Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

NCT04852887 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT04852887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04852887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
June 23, 2021
Completion date
July 31, 2041
Enrollment
1,670 (estimated)
Sites
832

Conditions

As the registry lists them; a condition with its own page is linked.

stage i breast cancer